The top 5 vaccines by 2020

Pfizer's ($PFE) Prevnar 13 currently dominates the list of the world's best-selling vaccines--and that won't be changing anytime soon, according to a new report from EvaluatePharma. In fact, it's expected to widen its lead, with sales growing more than 61% over the next 5+ years; by 2020, it will be generating nearly $4 billion more than runner up Pentacel from Sanofi ($SNY), EP predicts.

As far as the rest of the list, however, EP anticipates a bit of shuffling. Merck's ($MRK) Gardasil, last year's No. 2 seller, will slide into third place to make room for Pentacel. And GlaxoSmithKline's ($GSK) Pediarix will inch up into fifth, knocking Merck's varicella jab Varivax out of the top 5.

Take a look at the specifics and check out how the 2020 forecasts stack up to the top 10 best-selling vaccines of 2013. You can also peruse the rest of EP's report by downloading it here. Questions? Comments? Let us know. -- Carly Helfand (email | Twitter)

The top 5 vaccines by 2020
Vaccine & Company
2013 Sales (billions)
2020 Sales (billions)
CAGR 2013-20

Pneumococcal infection

Diphtheria, pertussis/whooping cough; tetanus; polio; Haemophilus influenzae type B

Human papillomavirus (HPV)


Diphtheria; tetanus; pertussis/whooping cough; hepatitis B; polio
Courtesy of EvaluatePharma